Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dibasic sodium phosphate (Na₂HPO₄) is an inorganic small molecule used primarily as an osmotic laxative and a phosphate replacement agent. As a laxative, it works by increasing the osmotic pressure in the small intestine, which draws water into the lumen, resulting in bowel distension and stimulated peristalsis. This effect is commonly utilized for colon cleansing prior to colonoscopy or surgery, often in combination with monobasic sodium phosphate. In the context of electrolyte management, it is administered intravenously to treat or prevent hypophosphatemia in patients with restricted oral intake or impaired absorption. Additionally, it is a ubiquitous pharmaceutical excipient used for pH buffering and stabilization in a wide range of injectable, ophthalmic, and oral drug products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dibasic sodium phosphate.